193 related articles for article (PubMed ID: 30596803)
1. Validation of the Clinical Index of Stable Febrile Neutropenia (CISNE) model in febrile neutropenia patients visiting the emergency department. Can it guide emergency physicians to a reasonable decision on outpatient vs. inpatient treatment?
Moon H; Choi YJ; Sim SH
PLoS One; 2018; 13(12):e0210019. PubMed ID: 30596803
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the MASCC and CISNE scores for identifying low-risk neutropenic fever patients: analysis of data from three emergency departments of cancer centers in three continents.
Ahn S; Rice TW; Yeung SJ; Cooksley T
Support Care Cancer; 2018 May; 26(5):1465-1470. PubMed ID: 29168032
[TBL] [Abstract][Full Text] [Related]
3. Application of the MASCC and CISNE Risk-Stratification Scores to Identify Low-Risk Febrile Neutropenic Patients in the Emergency Department.
Coyne CJ; Le V; Brennan JJ; Castillo EM; Shatsky RA; Ferran K; Brodine S; Vilke GM
Ann Emerg Med; 2017 Jun; 69(6):755-764. PubMed ID: 28041827
[TBL] [Abstract][Full Text] [Related]
4. CISNE versus MASCC: Identifying low risk febrile neutropenic patients.
Mohindra R; Mathew R; Yadav S; Aggarwal P
Am J Emerg Med; 2020 Nov; 38(11):2259-2263. PubMed ID: 31864874
[TBL] [Abstract][Full Text] [Related]
5. Accuracy of the Multinational Association of Supportive Care in Cancer (MASCC) and Clinical Index of Stable Febrile Neutropenia (CISNE) scores for predicting serious complications in adult patients with febrile neutropenia: A systematic review and meta-analysis.
Zheng B; Toarta C; Cheng W; Taljaard M; Reaume N; Perry JJ
Crit Rev Oncol Hematol; 2020 May; 149():102922. PubMed ID: 32244162
[TBL] [Abstract][Full Text] [Related]
6. Can Risk Stratification Tools Be Utilized to Safely Discharge Low-Risk Febrile Neutropenic Patients from the Emergency Department?
Chen AY; Gottlieb M; Vilke GM; Coyne C
J Emerg Med; 2023 Jan; 64(1):111-118. PubMed ID: 36641256
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the clinical Index of Stable febrile neutropenia risk stratification system for management of febrile neutropenia in gynecologic oncology patients.
Monuszko KA; Albright B; Katherine Montes De Oca M; Thao Thi Nguyen N; Havrilesky LJ; Davidson BA
Gynecol Oncol Rep; 2021 Aug; 37():100853. PubMed ID: 34504931
[TBL] [Abstract][Full Text] [Related]
8. Current management of chemotherapy-induced neutropenia in adults: key points and new challenges: Committee of Neoplastic Supportive-Care (CONS), China Anti-Cancer Association Committee of Clinical Chemotherapy, China Anti-Cancer Association.
Ba Y; Shi Y; Jiang W; Feng J; Cheng Y; Xiao L; Zhang Q; Qiu W; Xu B; Xu R; Shen B; Luo Z; Xie X; Chang J; Wang M; Li Y; Shuang Y; Niu Z; Liu B; Zhang J; Zhang L; Yao H; Xie C; Huang H; Liao W; Chen G; Zhang X; An H; Deng Y; Gong P; Xiong J; Yao Q; An X; Chen C; Shi Y; Wang J; Wang X; Wang Z; Xing P; Yang S; Zhou C
Cancer Biol Med; 2020 Nov; 17(4):896-909. PubMed ID: 33299642
[TBL] [Abstract][Full Text] [Related]
9. Can MASCC and CISNE scores predict delays of lung cancer chemotherapy after febrile neutropenia?
Ono Y; Hayama N; Hattori S; Ito Y; Oguma T; Sakamaki F; Asano K
Thorac Cancer; 2022 Dec; 13(24):3504-3509. PubMed ID: 36330990
[TBL] [Abstract][Full Text] [Related]
10. Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study.
Carmona-Bayonas A; Jiménez-Fonseca P; Virizuela Echaburu J; Antonio M; Font C; Biosca M; Ramchandani A; Martínez J; Hernando Cubero J; Espinosa J; Martínez de Castro E; Ghanem I; Beato C; Blasco A; Garrido M; Bonilla Y; Mondéjar R; Arcusa Lanza MÁ; Aragón Manrique I; Manzano A; Sevillano E; Castañón E; Cardona M; Gallardo Martín E; Pérez Armillas Q; Sánchez Lasheras F; Ayala de la Peña F
J Clin Oncol; 2015 Feb; 33(5):465-71. PubMed ID: 25559804
[TBL] [Abstract][Full Text] [Related]
11. Management of febrile neutropenia in malignancy using the MASCC score and other factors: Feasibility and safety in routine clinical practice.
Kumar P; Bajpai J; Shetty N; Medekar A; Kurkure PA; Ghadyalpatil N; Gupta S; Noronha V; Kanujia A; Parikh P; Banavali SD
Indian J Cancer; 2014; 51(4):491-5. PubMed ID: 26842174
[TBL] [Abstract][Full Text] [Related]
12. [Modalities of management of cancer patients with febrile neutropenia in the oncology emergency unit of Gustave-Roussy and their related costs].
Borget I; Antoun S; Chachaty E; Gachot B; Alibay A; Di Palma M; Merad M
Bull Cancer; 2014 Oct; 101(10):925-31. PubMed ID: 25373692
[TBL] [Abstract][Full Text] [Related]
13. Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings.
Weycker D; Barron R; Kartashov A; Legg J; Lyman GH
J Oncol Pharm Pract; 2014 Jun; 20(3):190-8. PubMed ID: 23824496
[TBL] [Abstract][Full Text] [Related]
14. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice.
Innes H; Lim SL; Hall A; Chan SY; Bhalla N; Marshall E
Support Care Cancer; 2008 May; 16(5):485-91. PubMed ID: 17899215
[TBL] [Abstract][Full Text] [Related]
15. Performance of the clinical index of stable febrile neutropenia (CISNE) in different types of infections and tumors.
Carmona-Bayonas A; Jiménez-Fonseca P; Virizuela J; Antonio M; Font C; Biosca M; Ramchandani A; Martinez-Garcia J; Hernando J; Espinosa J; de Castro EM; Ghanem I; Beato C; Blasco A; Garrido M; Mondéjar R; Arcusa MÁ; Aragón I; Manzano A; Sevillano E; Castañón E; Ayala F;
Clin Transl Oncol; 2017 Mar; 19(3):386-395. PubMed ID: 27525978
[TBL] [Abstract][Full Text] [Related]
16. Clinical factors predicting return emergency department visits in chemotherapy-induced febrile neutropenia patients.
Heo S; Jeon K; Park B; Ko RE; Kim T; Hwang SY; Yoon H; Shin TG; Cha WC; Lee SU
Am J Emerg Med; 2023 May; 67():90-96. PubMed ID: 36821961
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of procalcitonin and lipopolysaccharide binding protein in cancer patients with chemotherapy-associated febrile neutropenia presenting to an emergency department.
García de Guadiana-Romualdo L; Cerezuela-Fuentes P; Español-Morales I; Esteban-Torrella P; Jiménez-Santos E; Hernando-Holgado A; Albaladejo-Otón MD
Biochem Med (Zagreb); 2019 Feb; 29(1):010702. PubMed ID: 30591812
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of complete blood count parameters to predict poor outcomes in cancer patients with febrile neutropenia presenting to the emergency department.
Choi A; Park I; Lee HS; Chung J; Kim MJ; Park YS
Ann Med; 2022 Dec; 54(1):599-609. PubMed ID: 35175159
[TBL] [Abstract][Full Text] [Related]
19. A comparison of ED and direct admission care of cancer patients with febrile neutropenia.
Owolabi DK; Rowland R; King L; Miller R; Hegde GG; Shang J; Lister J; Venkat A
Am J Emerg Med; 2015 Jul; 33(7):966-9. PubMed ID: 25959844
[TBL] [Abstract][Full Text] [Related]
20. Emergency Ambulatory Management of Low-Risk Febrile Neutropenia: Multinational Association for Supportive Care in Cancer Fits-Real-World Experience From a UK Cancer Center.
Marshall W; Campbell G; Knight T; Al-Sayed T; Cooksley T
J Emerg Med; 2020 Mar; 58(3):444-448. PubMed ID: 31744709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
